Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Free Cash Flow: 2016-2025

Historic Free Cash Flow for Akebia Therapeutics (AKBA) over the last 10 years, with Sep 2025 value amounting to $28.0 million.

  • Akebia Therapeutics' Free Cash Flow rose 518.52% to $28.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.2 million, marking a year-over-year increase of 183.50%. This contributed to the annual value of -$40.7 million for FY2024, which is 74.02% down from last year.
  • According to the latest figures from Q3 2025, Akebia Therapeutics' Free Cash Flow is $28.0 million, which was up 26.14% from $22.2 million recorded in Q2 2025.
  • Akebia Therapeutics' Free Cash Flow's 5-year high stood at $33.8 million during Q3 2022, with a 5-year trough of -$70.8 million in Q1 2021.
  • In the last 3 years, Akebia Therapeutics' Free Cash Flow had a median value of -$6.7 million in 2024 and averaged -$2.5 million.
  • Per our database at Business Quant, Akebia Therapeutics' Free Cash Flow plummeted by 378.18% in 2024 and then spiked by 518.52% in 2025.
  • Over the past 5 years, Akebia Therapeutics' Free Cash Flow (Quarterly) stood at -$62.8 million in 2021, then grew by 12.94% to -$54.7 million in 2022, then surged by 95.78% to -$2.3 million in 2023, then crashed by 93.59% to -$4.5 million in 2024, then skyrocketed by 518.52% to $28.0 million in 2025.
  • Its Free Cash Flow was $28.0 million in Q3 2025, compared to $22.2 million in Q2 2025 and -$13.6 million in Q1 2025.